Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 study of dulaglutide added to insulin in type 2 diabetes
jRCT1080223318Phase 4
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Dulaglutide + insulin arm with Placebo / dulaglutide + insulin arm (2 arms).
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080223318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223318.